Evaluation of the Prognostic value of the Prechemotherapy Platelet to Lymphocyte Ratio in Malignant Pleural Mesothelioma

Abstract

Abstract Background The prognostic value of Platelet-to-lymphocyte ratio (PLR) in patients with malignant pleural mesothelioma is still indistinct. We conducted this study to assess the prognostic significance of pretreatment PLR in patients with MPM. Aim of the Work to assess the prognostic significance of pre-treatment PLR in patients with MPM. Material and Methods we retrospectively reviewed 1!0 patients treated for MPM with chemotherapy in Ain-Shams University hospital, Clinical Oncology department between January 2013 and December 2017. Pre-treatment CBC was available for the 110 patients to calculate PLR by dividing the absolute platelet count by the absolute lymphocytic count. Results Out of 110 patients with available pre-treatment complete blood picture, population age ranged from 28 to 70 years. Male to female ratio was 5:6 .Epithelioid subtype represent 85% of cases. Stages III and IV present 48.2% and 35.5, respectively while stages I and II present 3.6% and 12.7%, respectively. The median PLR in the study population was found to be 177.9, Conclusion PLR is an easy , reproducible and inexpensive prognostic factor that needs to be more investigated in MPM.